FI971486A - Alfa-interferonin stabiilit vesiliuosformulaatiot - Google Patents

Alfa-interferonin stabiilit vesiliuosformulaatiot Download PDF

Info

Publication number
FI971486A
FI971486A FI971486A FI971486A FI971486A FI 971486 A FI971486 A FI 971486A FI 971486 A FI971486 A FI 971486A FI 971486 A FI971486 A FI 971486A FI 971486 A FI971486 A FI 971486A
Authority
FI
Finland
Prior art keywords
alfa
interferon
stable aqueous
interferon alfa
aqueous formulations
Prior art date
Application number
FI971486A
Other languages
English (en)
Swedish (sv)
Other versions
FI116558B (fi
FI971486A0 (fi
Inventor
Pui-Ho C Yuen
Douglas F Kline
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of FI971486A publication Critical patent/FI971486A/fi
Publication of FI971486A0 publication Critical patent/FI971486A0/fi
Application granted granted Critical
Publication of FI116558B publication Critical patent/FI116558B/fi

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/21Interferons [IFN]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/21Interferons [IFN]
    • A61K38/212IFN-alpha
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
FI971486A 1994-10-11 1997-04-10 Alfa-interferonin stabiilit vesiliuosformulaatiot FI116558B (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US32981394 1994-10-11
US08/329,813 US5766582A (en) 1994-10-11 1994-10-11 Stable, aqueous alfa interferon solution formulations
US9512362 1995-10-10
PCT/US1995/012362 WO1996011018A1 (en) 1994-10-11 1995-10-10 Stable, aqueous alfa interferon solution formulations

Publications (3)

Publication Number Publication Date
FI971486A true FI971486A (fi) 1997-04-10
FI971486A0 FI971486A0 (fi) 1997-04-10
FI116558B FI116558B (fi) 2005-12-30

Family

ID=23287133

Family Applications (2)

Application Number Title Priority Date Filing Date
FI971486A FI116558B (fi) 1994-10-11 1997-04-10 Alfa-interferonin stabiilit vesiliuosformulaatiot
FI20055562A FI117377B (fi) 1994-10-11 2005-10-19 Kelatointiaineen käyttö alfatyyppistä interferonia sisältävässä, stabiilissa vesiformulaatiossa

Family Applications After (1)

Application Number Title Priority Date Filing Date
FI20055562A FI117377B (fi) 1994-10-11 2005-10-19 Kelatointiaineen käyttö alfatyyppistä interferonia sisältävässä, stabiilissa vesiformulaatiossa

Country Status (25)

Country Link
US (2) US5766582A (fi)
EP (2) EP0970703B1 (fi)
JP (2) JP3978228B2 (fi)
KR (1) KR100401401B1 (fi)
CN (1) CN1102408C (fi)
AT (2) ATE245033T1 (fi)
AU (1) AU708337B2 (fi)
BR (1) BR9509313A (fi)
CA (1) CA2201749C (fi)
CZ (1) CZ296961B6 (fi)
DE (2) DE69531314T2 (fi)
DK (1) DK0777495T3 (fi)
ES (2) ES2148568T3 (fi)
FI (2) FI116558B (fi)
GR (1) GR3034619T3 (fi)
HK (1) HK1008813A1 (fi)
HU (1) HU225494B1 (fi)
NO (1) NO320604B1 (fi)
NZ (1) NZ294464A (fi)
PL (1) PL183797B1 (fi)
PT (1) PT777495E (fi)
RU (1) RU2157236C2 (fi)
SK (1) SK282949B6 (fi)
UA (1) UA42028C2 (fi)
WO (1) WO1996011018A1 (fi)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030190307A1 (en) 1996-12-24 2003-10-09 Biogen, Inc. Stable liquid interferon formulations
ID28470A (id) * 1998-03-26 2001-05-24 Schering Corp Formulasi-formulasi untuk perlindungan terhadap konjugasi polietilen glikol-interferon alfa
US6180096B1 (en) 1998-03-26 2001-01-30 Schering Corporation Formulations for protection of peg-interferon alpha conjugates
BR9910505A (pt) 1998-05-15 2001-01-02 Schering Corp Terapia de combinação compreendendo ribavirina e interferon alfa em pacientes cândidos de tratamento antiviral tendo infecção crÈnica por hepatite c
US6281337B1 (en) 1998-11-12 2001-08-28 Schering Corporation Methods for conversion of protein isoforms
ATE409706T1 (de) 1998-11-12 2008-10-15 Schering Corp Verfahren zur umwandlung von interferon-isoformen und daraus hergestellte produkte
US7402559B2 (en) * 1999-03-24 2008-07-22 Msh Pharma, Incorporated Composition and method of treatment for urogenital conditions
NZ514629A (en) * 1999-04-08 2004-02-27 Schering Corp PEGylated interferon-alpha administered at about 4.5- 9.0 micrograms/kg/week as a renal cell carcinoma treatment
US6362162B1 (en) 1999-04-08 2002-03-26 Schering Corporation CML Therapy
US6605273B2 (en) 1999-04-08 2003-08-12 Schering Corporation Renal cell carcinoma treatment
ATE296639T1 (de) 1999-04-08 2005-06-15 Schering Corp Melanoma therapie
US6923966B2 (en) 1999-04-08 2005-08-02 Schering Corporation Melanoma therapy
DK1181036T3 (da) * 1999-04-09 2008-11-24 Ortho Mcneil Pharm Inc Farmaceutiske sammensætninger af erythropoietin
KR100399156B1 (ko) * 1999-11-19 2003-09-26 주식회사 엘지생명과학 α-인터페론의 용액제형
CN1175901C (zh) * 1999-12-06 2004-11-17 天津华立达生物工程有限公司 一种稳定的干扰素水溶液
CA2396503A1 (en) 1999-12-14 2001-06-21 Jeffrey W. Steaffens Stabilizing diluent for polypeptides and antigens
JP4536194B2 (ja) * 2000-02-17 2010-09-01 大日本住友製薬株式会社 安定な注射用製剤
CN1245215C (zh) 2001-02-28 2006-03-15 四川省生物工程研究中心 重组高效复合干扰素用作乙型肝炎表面抗原和e抗原抑制剂
NZ528750A (en) * 2001-04-04 2005-10-28 Alza Corp Transdermal electrotransport delivery device including an antimicrobial compatible reservoir composition
WO2002083165A1 (fr) * 2001-04-10 2002-10-24 Sumitomo Pharmaceuticals Co., Ltd. Preparations stables destinees a etre injectees
LT4947B (lt) 2001-09-26 2002-08-26 Biotechnologijos Institutas Interferono alfa farmacinė kompozicija
US20050232899A1 (en) * 2002-05-31 2005-10-20 Aradigm Corporation Compositions methods and systems for pulmonary delivery of recombinant human interferon alpha-2b
US6830744B2 (en) * 2002-05-31 2004-12-14 Aradigm Corporation Compositions methods and systems for pulmonary delivery of recombinant human interferon alpha-2b
US20040058895A1 (en) * 2002-09-18 2004-03-25 Bone Care International, Inc. Multi-use vessels for vitamin D formulations
US20040053895A1 (en) * 2002-09-18 2004-03-18 Bone Care International, Inc. Multi-use vessels for vitamin D formulations
US7148211B2 (en) * 2002-09-18 2006-12-12 Genzyme Corporation Formulation for lipophilic agents
US20040175359A1 (en) * 2002-11-12 2004-09-09 Desjarlais John Rudolph Novel proteins with antiviral, antineoplastic, and/or immunomodulatory activity
US7585647B2 (en) 2003-08-28 2009-09-08 Guangwen Wei Nucleic acid encoding recombinant interferon
US8906676B2 (en) 2004-02-02 2014-12-09 Ambrx, Inc. Modified human four helical bundle polypeptides and their uses
CN1724567B (zh) * 2004-07-22 2010-08-18 北京三元基因工程有限公司 一种稳定的重组人干扰素α1b水溶液
MX2007001663A (es) 2004-08-12 2007-04-10 Schering Corp Formulacion de interferon pegilado estable.
US20060204474A1 (en) * 2005-02-25 2006-09-14 Coroneo Minas T Treatment of epithelial layer lesions
ES2302402B1 (es) 2005-06-16 2009-05-08 Proyecto De Biomedicina Cima, S.L. Uso de una citoquina de la familia de interleuquina-6 en la preparacion de una composicion para administracion combinada con interferon-alfa.
CU23432B6 (es) * 2005-11-02 2009-10-16 Ct Ingenieria Genetica Biotech Formulaciones estabilizadas que contienen a los interferones gamma y alfa en proporciones potenciadoras
US8679472B1 (en) 2006-10-05 2014-03-25 Merck, Sharp & Dohme Corp. Crystal of human interferon alpha 2B in complex with zinc
AU2008247815B2 (en) 2007-05-02 2012-09-06 Ambrx, Inc. Modified interferon beta polypeptides and their uses
CN101918579A (zh) * 2007-10-22 2010-12-15 先灵公司 完全人抗-vegf抗体和使用方法
US20110184379A1 (en) * 2008-03-27 2011-07-28 Medtronic, Inc. Method and system to define patient specific therapeutic regimens by means of pharmacokinetic and pharmacodynamic tools
US20110293557A1 (en) 2008-06-13 2011-12-01 Proyecto De Biomedicina Cima, S.L. Conjugates for the administration of biologically active compounds
EP3228320B1 (de) 2008-10-17 2019-12-18 Sanofi-Aventis Deutschland GmbH Kombination von einem insulin und einem glp-1-agonisten
KR101303388B1 (ko) 2010-10-26 2013-09-03 한미사이언스 주식회사 지속형 인터페론 알파 결합체의 액상 제제
CN103732242A (zh) 2011-06-23 2014-04-16 迪格纳生物技术公司 用与IFN-α2b组合的IFN-α5在患者群体中治疗慢性丙型肝炎
KR20150074167A (ko) 2012-10-26 2015-07-01 루핀 리미티드 Peg 인터페론 알파-2b의 안정한 약학 조성물
CN110354255B (zh) 2013-04-03 2024-05-14 赛诺菲 通过长效胰岛素制剂治疗糖尿病
US9388239B2 (en) 2014-05-01 2016-07-12 Consejo Nacional De Investigation Cientifica Anti-human VEGF antibodies with unusually strong binding affinity to human VEGF-A and cross reactivity to human VEGF-B
ES2524516B1 (es) * 2014-05-29 2015-03-31 Grifols Worldwide Operations Limited Procedimiento de preparación de albúmina humana con nivel de oxígeno disuelto reducido
EP3200767A1 (en) * 2014-09-23 2017-08-09 F.Hoffmann-La Roche Ag Stable, benzyl alcohol-free aqueous solution formulations containing alpha-type interferon
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第2型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第2型糖尿病病患之治療
MA45276A (fr) * 2015-06-18 2018-04-25 Sage Therapeutics Inc Solutions de stéroïdes neuroactifs et leurs méthodes d'utilisation
RU2623050C2 (ru) * 2015-12-03 2017-06-21 Виталий Эдуардович Боровиков Раствор хондроитина сульфата для внутримышечного введения и способ его получения
KR200492470Y1 (ko) 2020-03-26 2020-10-21 사공탁 빌라 주택용 쓰레기 수거함
RU2768656C1 (ru) * 2021-09-10 2022-03-24 Илья Александрович Марков Противовирусное средство в жидкой форме и способ его приготовления
CN113797318B (zh) * 2021-10-26 2023-06-30 深圳科兴药业有限公司 一种干扰素组合物及其制备方法和应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0082481B2 (en) * 1981-12-23 1990-09-12 Schering Corporation Stabilised alpha-interferon formulations and their preparation
JPS59176216A (ja) * 1983-03-28 1984-10-05 Sumitomo Chem Co Ltd 有用なインタ−フエロン製剤
US4680175A (en) * 1984-02-07 1987-07-14 Interferon Sciences, Inc. Interferon administration vehicles
JPS60243028A (ja) * 1984-04-28 1985-12-03 Kyowa Hakko Kogyo Co Ltd インタ−フエロンの可溶化方法
US4606917A (en) * 1984-10-03 1986-08-19 Syntex (U.S.A) Inc. Synergistic antiviral composition
US4857316A (en) * 1984-10-03 1989-08-15 Syntex (U.S.A.) Inc. Synergistic antiviral composition
JPS61277633A (ja) * 1985-05-31 1986-12-08 Toray Ind Inc インタ−フエロン組成物
US4847079A (en) * 1985-07-29 1989-07-11 Schering Corporation Biologically stable interferon compositions comprising thimerosal
EP0284249A1 (en) * 1987-03-13 1988-09-28 Interferon Sciences, Inc. Lyophilized lymphokine composition
US5266310A (en) * 1987-09-17 1993-11-30 Boehringer Ingelheim International Gmbh Stabilization of therapeutically active proteins in pharmaceutical preparations
IL88233A (en) * 1987-11-03 1993-08-18 Genentech Inc Gamma interferon formulation
DE4126983A1 (de) * 1991-08-15 1993-02-18 Boehringer Mannheim Gmbh Verfahren zur herstellung von humanprotein-enthaltenden, konservierten arzneimitteln fuer infusions- oder injektionszwecke
JP3292894B2 (ja) * 1993-05-12 2002-06-17 日本電信電話株式会社 集積化受光回路

Also Published As

Publication number Publication date
HK1008813A1 (en) 1999-05-21
CZ110497A3 (en) 1997-09-17
SK282949B6 (sk) 2003-01-09
WO1996011018A1 (en) 1996-04-18
NZ294464A (en) 1999-03-29
DE69531314D1 (de) 2003-08-21
DE69531314T2 (de) 2004-05-13
KR970706017A (ko) 1997-11-03
CA2201749A1 (en) 1996-04-18
BR9509313A (pt) 1998-01-27
ES2148568T3 (es) 2000-10-16
EP0970703B1 (en) 2003-07-16
EP0777495A1 (en) 1997-06-11
NO320604B1 (no) 2005-12-27
DE69518084D1 (de) 2000-08-24
JP3978228B2 (ja) 2007-09-19
UA42028C2 (uk) 2001-10-15
MX9702578A (es) 1997-07-31
PT777495E (pt) 2000-12-29
DE69518084T2 (de) 2001-03-22
JPH10506912A (ja) 1998-07-07
GR3034619T3 (en) 2001-01-31
FI116558B (fi) 2005-12-30
CN1102408C (zh) 2003-03-05
AU708337B2 (en) 1999-08-05
CA2201749C (en) 1999-06-15
PL183797B1 (pl) 2002-07-31
AU3727995A (en) 1996-05-02
NO971633L (no) 1997-04-10
FI20055562A (fi) 2005-10-19
US5766582A (en) 1998-06-16
CZ296961B6 (cs) 2006-08-16
FI117377B (fi) 2006-09-29
ATE194774T1 (de) 2000-08-15
PL319603A1 (en) 1997-08-18
DK0777495T3 (da) 2000-11-06
FI971486A0 (fi) 1997-04-10
SK43997A3 (en) 1997-10-08
HUT77287A (hu) 1998-03-30
ATE245033T1 (de) 2003-08-15
EP0777495B1 (en) 2000-07-19
EP0970703A1 (en) 2000-01-12
ES2198830T3 (es) 2004-02-01
NO971633D0 (no) 1997-04-10
US5935566A (en) 1999-08-10
CN1160355A (zh) 1997-09-24
HU225494B1 (en) 2007-01-29
KR100401401B1 (ko) 2004-02-18
JP2006193536A (ja) 2006-07-27
RU2157236C2 (ru) 2000-10-10

Similar Documents

Publication Publication Date Title
FI971486A (fi) Alfa-interferonin stabiilit vesiliuosformulaatiot
DK1308170T3 (da) Törret blodfaktorpræparat indeholdende trehalose
ATE355850T1 (de) Lyophilisierte hgf-zubereitungen
IT1247945B (it) Agente avente attivita' batteriostatica e battericida
NZ505821A (en) Pharmaceutical compositions of uridine triphosphate
ATE124869T1 (de) Stabilisierung von calcitonin enthaltenden pharmazeutischen verbindungen.
FI943705A0 (fi) Farmaseuttiset koostumukset
ATE274903T1 (de) Antivirale mittel
MX9305523A (es) Composiciones quimoterapeuticas mejoradas frente a infecciones microbianas en peces, la reparacion y uso de las mismas.
DK443988D0 (da) Injektionspraeparat indeholdende modificeret tpa
FR2718923B1 (fr) Composition désinfectante en solution aqueuse renfermant de l'orthophtalaldéhyde.
KR870008581A (ko) 안정하고 주사가능한 1,4-디히드록시-5,8-비스 [2-(2-히드록시에틸아미노)에틸아미노]안트라퀴논, 디히드로클로라이드의 약학적 배합제제
DK0506563T3 (da) Alginsyresuspension
SE9502927D0 (sv) Solution containing IGF-I
BR0014964A (pt) Composição em barra detergente conformada sólida moldada por fusão
RU2002120178A (ru) Водный раствор интерферона-альфа-два человека для инъекций

Legal Events

Date Code Title Description
FG Patent granted

Ref document number: 116558

Country of ref document: FI

PC Transfer of assignment of patent

Owner name: MERCK SHARP & DOHME CORP.

MA Patent expired